This study evaluates the prognostic significance of quantitative chimerism to monitor minimal residual disease and predict relapse in acute leukemia (AL) patients following allogeneic hematopoietic SCT (HSCT). The quantitative chimerism levels of 129 AL patients were measured using RQ-PCR based on 29 sequence polymorphisms. Receiver-operating characteristic curve indicated that the optimal cutoff point to predict an inevitable relapse was 1.0%, which results in 100.0% sensitivity and 79.6% specificity.The relapse rate of patients with chimerism 41.0% at 2 years was 55.0%, whereas that for patients with chimerism o 1.0% was 0%(P = 0.000). Quantitative chimerism 41.00% indicated a higher probability of relapse. Cox multivariate analysis indicated that quantitative chimerism 41.00% was associated with lower disease-free survival (hazard ratio (HR) = 10.825; 95% confidence interval (CI) = 4.704-24.912, P = 0.000) and lower OS (HR = 8.681; 95% CI = 3.728-20.212, P = 0.000). Patients (24/47 with quantitative chimerism 41.00%) who received preemptive modified DLI immunotherapy had significantly lower relapse rate (37.5%) than those (n = 9) who did not (100%; P = 0.001). Thus, quantitative chimerism is an independent prognostic factor that predicts clinical outcomes after HSCT and provides a guide for suitable interventions.
INTRODUCTION
Allogeneic hematopoietic SCT (allo-HSCT) is an effective therapy for acute leukemia (AL), but relapse remains an important problem.
1,2 Therapy options for relapse include immunesuppression discontinuation, chemotherapy reinduction, DLI and other transplantation used alone or in combination. However, the efficacy of these interventions is limited. The significance of DLI is limited when initiated during frank hematologic relapse, and the requirement for high cell doses increases the risk of severe GVHD. 3 Therefore, impending relapse should be detected. Previous reports showed that impending relapse can be indicated by mixed chimerism (MC), which can be prevented by preemptive immunotherapy (that is, discontinuation of immunosuppression and adoptive DLI). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Quantitative chimerism based on real-time PCR by amplification of sequence polymorphisms (SP) has recently been established. [15] [16] [17] [18] This technique is superior to STR-PCR in terms of identifying patients who are at high risk for relapse after transplantation. However, no adequate clinical data confirmed that increased sensitivity in the detection of residual host cells improves the capability of chimerism tests to predict relapse. This study thus aims to investigate whether quantitative chimerism can be a useful method for monitoring early relapse of AL after allo-HSCT. The chimerism levels of 129 AL patients were dynamically measured at precise and sequential time points using RQ-PCR based on SP markers. The relationship between the quantitative chimerism value and probability of relapse after HSCT was also analyzed. Finally, the preliminary cutoff levels of quantitative chimerism that can be used to direct suitable interventions were determined.
PATIENTS AND METHODS Patients
Between January 2010 and December 2012, we enrolled 129 AL patients treated with allo-HSCT at the Peking University Institute of Hematology. A total of 961 BM samples from these patients were collected after allo-HSCT. All patients provided informed consent for treatment under a protocol reviewed and approved by the Peking University Institute of Hematology. The characteristics of the patients and transplantations are summarized in Table 1 .
Transplant protocols
All patients received myeloablative conditioning regimens. [19] [20] [21] BU/CYbased conditioning therapy was administered (4 mg/kg/d BU, orally for 3 days; and 1.8 g/m 2 /d CY, i.v. for 2 days). A single dose of semustine (250 mg/m 2 , orally) was administered to all patients, whereas a single dose of cytarabine (2 g/m 2 /d, i.v.) was administered to patients who had a matched sibling. HLA-mismatched and HSCT-matched unrelated patients were also given cytarabine (4 g/m 2 /d) and antithymocyte globulin (2.5 mg/ kg/d, SangStat, Lyon, France) i.v. for 2 days and 4 consecutive days, respectively. All subjects received G-CSF-mobilized BM and blood cells. Prophylaxis against GVHD included the treatment with CsA and short-term MTX with mycophenolate mofetil. On day 9, CsA (2.5 mg/kg) was started on i.v. Mycophenolate mofetil was administered orally (0.5 g every 12 h) from day 9 before the transplantation until day 30 after the transplantation. At 30 d after the transplantation, 0.25 g of mycophenolate mofetil was given every 12 h for 1-2 months. On day 1, MTX (15 mg/m 2 ) was administered i.v., and 10 mg/m 2 MTX was given on days 3, 6 and 11 after transplantation. Immunosuppression regimens were discontinued for all patients who had an AL relapse or a detected increasing chimerism while still taking immunosuppressive agents.
Sample preparation
A total of 961 BM samples from 129 allo-HSCT patients were obtained for the investigation of chimerism after transplantation. The monitored chimerism time points included 1, 2, 3, 6, 9 and 12 months, and every 6 months thereafter after HSCT. More frequent chimerism monitoring was performed in some patients depending on their individual condition.
Quantitative chimerism analysis
Quantitative chimerism analysis was performed using real-time PCR based on 29 SP system markers, including short deletions or insertions according to Alizadeh et al. 15 and single nucleotide polymorphisms according to Mass et al. [16] [17] [18] In cases of sex-mismatched allo-HSCT, Y-chromosomespecific sequences from the SMCY gene were used. 16 On the basis of SP-PCR, recipient genotype discrimination was possible in 97.0% (98/101) of specimens with a mean of 2.5 informative markers per recipient/donor pair (range 1-7). The use of serial dilutions of plasmids containing specific SP markers, linear correlation of 0.99, slope between − 3.2 and − 3.7, and sensitivity of 0.1% were proven as reproducible. An accurate detection of autologous signals within the range of 0.1-30% was possible using this method. The accuracy below 5%, which was a very important range of autologous signals, was extraordinarily high (s.d. o 1.85%). The chimerism status was accurately quantified with a standard curve after normalization using the β-actin gene. All SP-specific standard curves and control gene standard curves had similar PCR efficiency. The minor differences could be corrected by the ratio of the copies of pre-HSCT recipient or donor samples on the specific SP marker and β-actin gene. The DNA content was considered to be insufficient for analysis when the β-actin gene was detected at a cycle threshold of 29. All samples were analyzed in duplicate. 22, 23 A quantitative recipient chimerism level 41.0% was defined as increasing mixed chimerism (IMC).
Minimal residual disease (MRD) monitoring and definition
The MRD level was determined via RQ-PCR and four-color flow cytometry (FCM) on BM aspirates after HSCT. 24, 25 The markers for MRD included leukemia-associated immunophenotypes and leukemia-associated genes (WT1, AML1-ETO, CBFB-MYH11 and BCR-ABL) assayed in diagnostic specimens. More than 0.001% of leukemia-associated immunophenotypes via four-color FCM or more than 10 − 4 of reciprocal fusion genes or 0.6% of WT1 gene via RQ-PCR in BM samples was considered as abnormal. The definition of MRD was two consecutive abnormalities for FCM or leukemiaassociated genes during a 15-30-day interval. mDLI After MRD and increasing chimerism were diagnosed, preemptive mDLI was performed to prevent relapse after HSCT. Post-transplantation immunesuppression was immediately tapered, and then discontinued in patients who were transplanted in less than 100 days. Patients who were transplanted in more than 100 days had immune suppression immediately discontinued. In patients without active GVHD, mDLI or IL-2 was given based on the availability of a DLI donor. Subcutaneous IL-2 was given at a dose of 1 × 10 6 U/d for 14 days. One or more subsequent cycles were given after a 14-day interval until 12 cycles unless the subject developed GVHD or higher than grade 3 toxicity based on the NCI CommonTerminology Criteria for Adverse Events Version 4.
26 Antileukemia chemotherapy was administered to patients 48-72 h prior to mDLI, and consisted of aclacinomycin 20 mg/d for 7 days and cytarabine 150 mg/m 2 for 7 days in patients with AML, and MTX 1 g/m 2 for 1 day in subjects with ALL. For mDLI, G-CSF-mobilized PBSCs were given instead of the more common unstimulated blood lymphocytes from the donor. After mDLI, patients received immunosuppressive drugs such as CsA or MTX to prevent GVHD. Patients who received mDLI from an HLA-identical related donor received GVHD prophylaxis for 2-4 weeks. However, patients who received mDLI from an HLA-matched unrelated or HLA-haploidentical donor received GVHD prophylaxis for 4-6 weeks at the discretion of the attending physicians (and usually depending on the patient's GVHD status after mDLI). The starting dose of CsA was 2.5 mg/kg/d, and was adjusted to maintain a plasma concentration 4100 ng/mL. Moreover, MTX was given at 10 mg i.v. on days 1, 4 and 8, and weekly thereafter for 2-6 weeks. [27] [28] [29] [30] Chimerism and MRD state were monitored at 1, 2, 3, 4.5, 6, 9 and12 months after the interventions, and at 6-month intervals thereafter.
Study definitions
Neutrophil engraftment had an ANC40.5 × 10 9 /L for 3 consecutive days. Platelet engraftment without transfusion had platelet count of 420 × 10 9 /L for 7 consecutive days. The diagnosis and grading of GVHD was established based on published criteria. 24, 26 Patients with malignancies in first or second CR1 or CR2, respectively of AL were categorized as 'standard risk'. Patients in more than the second CR of AL, not in remission, or had high-risk cytogenetics such as t(9;22) and t(4;11) were classified as 'high risk'. In addition, CR was defined as BM blasts o 5%, absence of blasts with Auer rods, absence of extramedullary disease, ANC 41.0 × 10 9 /L, platelet count 4100 × 10 9 /L and independence of red cell transfusions. PR included all hematological criteria of CR, BM blast percentage from 5 to 20% and a decrease of pretreatment BM blast percentage by a minimum of 50%. Patients who did not achieve either of the mentioned standards (for CR or PR) were classified as no remission (NR). Relapse was defined as the presence of more than 20% blasts in the BM or blasts at extramedullary sites, whereas relapse rate was the probability of leukemia recurrence. OS was calculated from the date of transplantation until death or last observation of patients' life. Disease-free survival (DFS) was described as the probability of being alive and free of disease at any point in time. MRD targets were also regularly examined within 2 weeks before transplantation. The MRD status before HSCT were defined as abnormal if they contained more than 0.001% of leukemiaassociated immunophenotypes via four-color FCM or more than 10 − 4 of reciprocal fusion genes or more than 0.6% of Wilms tumor gene 1 (WT1). 24, 25 Refractory disease included NR and PR patients before HSCT.
Statistical analysis
The reference date of 1 October 2013 was used to define the end of follow-up. The state of DFS and OS were calculated according to the Kaplan-Meier statistics. The differences in DFS and OS between groups were calculated using the log-rank test. Receiver-operating characteristic (ROC) analysis was performed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). A two-sided P-value of 0.05 was regarded as significant. The multivariate Cox regression analysis was applied to examine the independence of DFS predictive factors. The independence of categorical parameters was calculated using the χ 2 -test or Fisher's exact test, whereas Abbreviations: aGVHD = acute GVHD; cGVHD = chronic GVHD; HR = high risk; MRD = minimal residual disease; SR = standard risk.
the distribution of continuous variables was calculated using the Mann-Whitney U-test. In the landmark analyses, only patients at risk for relapse were included, that is, dead and relapsed patients at the time point analyzed were excluded, Po0.05 were considered significant.
RESULTS

General patient information
All patients achieved neutrophil engraftment at a mean time of 12 days (range 10-25 days). Seven patients achieved platelet engraftment after 100 days, and one died 5 months before platelet engraftment. The mean time of platelet engraftment was 14 days (range 8-80 days). By the 1 October 2013 end point, the median follow-up time was 24 months (range 3-46 months). A total of 45 patients (34.8%) developed acute GVHD, and 15 (11.6%) developed acute GVHD higher than the grade two. Three patients could not be evaluated for chronic GVHD because of death before day 100. In the remaining 126 patients, chronic GVHD developed in 44 patients (34.9%), and extensive chronic GVHD developed in 35 patients (27.8%). Overall, 26 patients (20.2%) relapsed after transplantation (median 6 months and range 3-32 months). A total of 32 patients (24.8%) died because of relapse (n = 22) or other causes of transplantation-related mortality (n = 10; infection, n = 7; cerebral hemorrhage, n = 1; hemorrhage of digestive tract, n = 1; and post-transplantation lympho-proliferative disorders, n = 1), shown in Tables 1 and 2 .
The chimerism levels and outcomes after HSCT in different groups The chimerism levels and outcomes in patients without increasing chimerism. A total of 129 patients were divided into two groups based on the chimerism levels after HSCT ( Figure 1 ). About 82 patients did not show chimerism levels higher than 1.0% within the follow-up period. The median follow-up time for these patients was 22 months (range 5-46 months). A total of 547 BM samples were collected from this group of patients. The median chimerism levels at 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36 months after HSCT were 0.19% (0.00-0.98%, n = 70), 0.18% (0.00-0.98%, n = 78), 0.17% (0.00-0.94%, n = 75), 0.12% (0.00-0.98%, n = 77), 0.09% (0.00-0.78%, n = 76), 0.08% (0.00-0.60%, n = 68), 0.06% (0.00-0.52%, n = 41), 0.08% (0.00-0.72%, n = 38), 0.12% (0.00-0.20%, n = 11) and 0.06% (0.00-0.22%, n = 13), respectively ( Figure 2 ). The chimerism levels were not significantly different among the groups at various time points (P40.05). None of the 82 patients developed relapse, whereas 75 maintained long-term remission and 4 accepted mDLI because of low-level MRD+. Seven patients died because of TRM.
In the normal chimerism group, patients accepted mDLI because of low level MRD+. One Ph+ALL patient had BM-MRD value of BCR-ABL (P190) 4.2%, FCM 0.05%, chimerism of BM 0.72%, chimerism of BM 1 month ago 0.00% and increasing recipient chimerism. However, the chimerism value was lower than 1.0%. Another M2 patient had BM MRD value of AML1/ETO 26.0%, FCM-, chimerism of BM was 0.90%, chimerism value of BM 1 month ago was 0.46% and increasing recipient chimerism. Another two patients accepted mDLI because of WT1 1.2 and 0.96%, respectively, and no increasing recipient chimerism was observed at the same time.
Dynamic monitoring of the level of quantitative chimerism after HSCT was important to determine the intensive intervention that should be performed.
The chimerism levels and outcomes in patients with increasing chimerism. About 47 patients showed chimerism levels higher than 1.0% within the follow-up period after HSCT. Six samples from six patients had chimerism 41.0% at the first month during follow-up, which returned to normal levels upon serial monitoring. The chimerism values were 1.8, 1.1, 2.34, 1.24, 1.76 and 1.04%. Five patients remained in the remission without intervention during follow up, and only one patient died at 8 months because of infection.
In eight patients, clinical relapse appeared concurrently with overt increasing chimerism. Relapse occurred at months 9, 4, 6, 5, 9, 23, 6 and 6 after HSCT, whereas the chimerism levels were 103.3, 65.5, 57.0, 34.6, 48.7, 40.7, 52.3 and 34.8%, respectively. These patients did not show any increasing chimerism before relapse. The median time from the last chimerism test to the relapse was 3 months (range1-6 months). Among the eight patients, seven died of relapse and one remained alive because of second transplantation.
The IMCs were observed before overt relapse in 33 patients. All patients were in complete hematological remission at the first instance the IMC was detected. About 24 patients accepted Figure 1 . Diagram of intervention strategy based on IMC and MRD.
preemptive mDLI, whereas 9 accepted IL-2 because of donor unavailability. The median chimerism level before therapy was 3.82% (1.10-13.08%, n = 33), and no significant difference between the chimerism levels of mDLI group and IL-2 group (P = 0.546) was observed (Table 3) . After preemptive mDLI therapy, the remission patients' chimerism values returned to normal level at 0.18% (0-0.54%, n = 15, P o0.05%). However, all relapse patients had high levels of mixed chimerism at 35.4% (28.4-110.5%, n = 18). Further analysis of this group revealed a striking difference between the preemptive mDLI-treated and -untreated patients. Nine (37.5%) of the 24 patients who accepted preemptive mDLI had relapses as compared with the nine (100%) of the nine patients who accepted IL-2 (P = 0.001, Table 3 ). Among the 24 patients who had preemptive mDLI according to the protocol, 15 regained CR. Thirteen of these 15 patients remained alive and disease-free during the remainder of follow-up (median 30 months, range12-46 months), and 2 died of infection at 19 and 24 months, respectively. All nine patients with increasing MC who accepted IL-2 had relapses, whereas seven died because of relapse and two survived after the second transplantation. Among the 18 relapse patients, the median time with increasing chimerism ahead of the relapse was 1 month (range 1-12 months). Twelve patients developed aGVHD (36.4%) after intervention, five patients developed ⩾ grade 2 aGVHD (15.2%); there were no significant differences in subjects receiving mDLI and IL-2 in the incidence of aGVHD (P = 0.825) and ⩾ grade 2 aGVHD (P = 0.692). Ten patients developed cGVHD (30.3%) after intervention; there was no significant difference between mDLI group and IL-2 group (P = 0.536); shown in Table 3 .
Relapse, DFS, OS and increasing chimerism after HSCT. An ROC analysis was performed to investigate the relationship between the relapse and highest chimerism level after HSCT in all patients. The area under the ROC curve value was 0.943 (95% confidence interval (CI) = 0.906-0.980, P = 0.000, Figure 3a) . These results indicated that a higher chimerism level was associated with a higher AL relapse.
Subsequently, the diagnostic accuracy of chimerism level was evaluated using various chimerism values as cutoff points. Results indicated that optimal cutoff point to predict an inevitable relapse was 1.0%. The use of this tentative cutoff value resulted in 100.0% sensitivity and 79.6% specificity of the chimerism levels on the ROC curve. In the Kaplan-Meier statistics, the cumulative incidence of relapse (CIR) rate of patients with chimerism 41.0% at 2 years was 55.0%, whereas 0% for those with chimerism o 1.0% (P = 0.000, Figure 3b ). All of these analyses suggested that chimerism level 41.0% indicated a high probability of relapse after HSCT.
In Kaplan-Meier statistics, chimerism level 41.0% indicated a significantly worse DFS, as seen in Figure 4a (P = 0.000). The relationship between the chimerism level and DFS was analyzed using a Cox multivariate analysis that considered several variables, including patients' age, sex, lineage type, HLA matching, status of disease before HSCT, occurrence of acute/chronic GVHDand the highest chimerism level after HSCT. Interestingly, only chimerism level 41.0% (hazard ratio (HR) = 10.825; 95% CI = 4.704-24.912, P = 0.000) were associated with lower DFS.
The Kaplan-Meier analysis indicated a significant difference in OS when the cutoff value of chimerism value was 1.0% (P = 0.000, Figure 5a ). The Cox multivariate analysis was also performed to investigate the relationship between OS and chimerism level after HSCT. The variables included patient's age, sex, lineage type, HLA matching, status of disease before HSCT, occurrence of acute/ chronic GVHDand the highest chimerism level after HSCT. Results showed that only chimerism 41.0% (HR = 8.681; 95% CI = 3.728 -20.212, P = 0.000) were associated with a lower OS.
In the landmark analyses, the median time of increasing chimerism was 5 months. We compared survival curves with or without mixed chimerism 41.0% before and at 6 months among non-relapsed survivors after 6 months until the last follow-up date. Kaplan-Meier statistics indicated a significantly lower DFS (P = 0.009) and OS (P = 0.023) in mixed chimerism 41.0% before and at 6 months group compared with the normal chimerism group. Cox multivariate analysis indicated that only mixed chimerism 41.0% before and at 6 months were associated with lower DFS (HR = 3.556; 95% CI = 1.284-9.845, P = 0.015) and lower OS (HR = 3.321; 95% CI = 1.104-9.990, P = 0.033). Mixed chimerism 41.0% before and at 6 months can predict clinical outcomes.
The relationship between those with preemptive mDLI and without preemptive mDLI was analyzed using a Cox multivariate analysis that considered several variables, including patient's age, sex, lineage type, HLA matching, status of disease before HSCT, occurrence of acute/chronic GVHD and with or without preemptive mDLI after increasing chimerism. The preemptive mDLI were associated with higher DFS (HR = 4.354; 95% CI = 1.647--11.511, P = 0.003), higher OS (HR = 2.997; 95% CI = 1.098-8.181, P = 0.032) and lower relapse (HR = 4.354; 95% CI = 1.647-11.511, P = 0.003). The Kaplan-Meier analysis indicated a significant difference in CIR, DFS and OS between patients with and without preemptive mDLI (P o 0.05, Figures 3c, 4b, 5b) . Preemptive mDLI can effectively decrease relapse after increasing chimerism.
We broke down and analyzed the data by AML and ALL with internvention, 14 AML patients accepted mDLI, 5 AML patients Quantitative chimerism:an independent prognosis indicator X-Y Qin et al accepted IL-2; Kaplan-Meier statistics indicated a significantly lower CIR (P = 0.004), higher DFS (P = 0.004) and OS (P = 0.002) in mDLI group compared with IL-2 group. Ten ALL patients accepted mDLI, four ALL patients accepted IL-2; Kaplan-Meier statistics did not find significant difference in CIR (P = 0.148), DFS (P = 0.148) and OS (P = 0.933) between the two groups. The outcomes of the 33 IMC patients after intervention were compared. The Kaplan-Meier analysis indicated significantly lower CIR (P = 0.004), significantly higher DFS (P = 0.004) and higher OS (P = 0.057) in mDLI group compared with IL-2 group; shown in Figures 3d, 4c , and 5c.
Correlation of chimerism with MRD analyses. All 33 patients who accepted therapy with increasing chimerism had MRD+ status; the overt relapse in eight patients without any sign had high level of chimerism and MRD+ simultaneously. However, six patients with slightly increasing chimerism at first month had MRD − . Only 4 patients in the normal chimerism group accepted therapy because of low level MRD+, whereas the remaining 78 had MRD-all throughout the time point.
DISCUSSION
Allo-HSCT is an effective therapy for AL, but relapse remains an important problem.
1,2 The limitation of DLI in treating pediatric AML or ALL in frank relapse has led to the investigation of preemptive DLI at the time of mixed chimerism. 31, 32 Previous studies have shown that decreasing donor chimerism heralds leukemia relapse. 4, 33 The use of serial chimerism analysis results in an advanced detection of the impending hematological relapse that provide time to collect donor cells for DLI. 34 Recently, this approach has been feasible in single-center and cooperative group settings. 31, 32 However, these studies were all obtained by the classical STR-PCR method. Recently, real-time PCR techniques aimed at the amplification of SPs have been established. Alizadeh et al. 15 first reported a set of 11 bi-allelic insertion/deletion sites P =0.000
Cumulative incidence of relapse Sensitivity using real-time PCR amplification for chimerism analysis. The limit of detection for the minor cell population is higher than that of STR-PCR, and is reported to be 0.1-0.001%. Subsequent studies demonstrated the possibility of accurate characterization of chimerism by real-time PCR. [16] [17] [18] Previous studies also demonstrated that real-time PCR techniques aimed at the amplification of SPs are superior to the classical STR-PCR. 22, 23, 35, [36] [37] [38] [39] However, no adequate clinical data confirm that increased sensitivity in the detection of residual host cells improves the ability of chimerism tests to predict relapse.
In our study, the effects of quantitative chimerism of 129 AL patients based on real-time PCR of SP markers in the posttransplantation period were evaluated. A ROC analysis was performed to investigate the relationship between the relapse and highest chimerism level following HSCT. The area under the ROC curve value was 0.943 (95% CI = 0.906-0.980, P = 0.000, Figure 3 ).ROC curve indicated that the optimal cutoff point to predict an inevitable relapse was 1.0%, which results in 100.0% sensitivity and 79.6% specificity. None of the 82 patients who showed chimerism levels lower than 1.0% had relapse within the follow-up period. However, the relapse rate of patients with chimerism 41.0% (n = 47) at 2 years was 55.0% (P = 0.000, Figure 3b ), quantitative chimerism 41.00% indicated a higher probability of relapse. Cox multivariate analysis indicated chimerism level 41.0% was associated with lower DFS (HR = 10.825; 95% CI = 4.704-24.912, P = 0.000) and lower OS (HR = 8.681; 95% CI = 3.728-20.212, P = 0.000). These results indicated that quantitative chimerism is an independent prognostic factor that predicts clinical outcomes after HSCT.
Traditional DLI with steady-state lymphocytes has been shown to effectively treat relapse, but often causes severe GVHD. [40] [41] [42] However, data from a previous study showed that replacing the steady-state lymphocytes with G-CSF-mobilized peripheral blood cells, and applying a short course of immunosuppressive agents (administration of CSA or MTX after DLI for 2-4 weeks) decreased the incidence of DLI-associated acute GVHD without affecting relapse or survival. 43 For patients with hematological relapse after receiving allo-HSCT, the donor G-CSF-mobilized peripheral blood cell infusion treatment group has a better outcome compared with chemotherapy. This finding has been demonstrated in patients under HLA-matched and HLA-mismatched/haploidentical T-cell-replete HSCT groups. 27, 44 Subsequent studies demonstrated that G-CSF-mobilized peripheral blood cell infusion treatment also has a prophylactic effect against relapse in high-risk leukemia patients after any types of HSCT. 28, 29 Recently, an mDLI regimen was developed using pre-DLI chemotherapy, G-CSF-mobilized peripheral blood cells and post-DLI immunosuppression. Our team concluded that the risk stratification directs the interventions with mDLI in MRD-positive patients who have standard-risk AL, which can prevent leukemia relapse and further improve transplant outcomes. 30 In the present study, patients with early-detected increasing chimerism accepted mDLI based on donor availability. Results revealed a striking difference between the mDLI group and IL-2 group. Nine (37.5%) of the 24 patients who were treated with mDLI for increasing MC had relapses as compared with those 9 (100%) of 9 patients who received IL-2 (P = 0.001, Table 3 ). The early mDLI treatment was associated with higher DFS (HR = 4.354; 95% CI = 1.647-11.511, P = 0.003), higher OS (HR = 2.997; 95% CI = 1.098-8.181, P = 0.032) and lower relapse (HR = 4.354; 95% CI = 1.647-11.511, P = 0.003). The preemptive mDLI can effectively decrease relapse and improve survival after early detection with increasing chimerism.
MRD should be monitored by using disease-specific PCR techniques, for example, T-cell-receptor-or Ig-gene rearrangement for ALL, and gene markers such as AML1-ETO, CBFBMYH11, NPM1, FLT3 and MLL-PTD for AML. 45 Expression of the WT1 gene is another promising marker for AL during the follow-up period after HSCT. However, not all AL patients have a specific MRD marker; over 50% of AML patients lack a specific fusion gene.
46
WT1 transcript levels were elevated in a total of 354 of 476 (74%) AML patients and 86 of 131 (66%) ALL patients. 47 The incidence of relapse at 3 years after HSCT was 18.1% in 709 MRD standard-risk AL patients. 30 The limit of quantitative chimerism is reported to be 0.1-0.001%. Recipient genotype discrimination was possible in 96-97%. 22, 39 The incidence of relapse was 0% in the normal chimerism group (n = 82) in this study, thus quantitative chimerism may serve as a surrogate marker for MRD. All 33 patients who accepted therapy with increasing chimerism had MRD+ status. In the normal chimerism group, four patients accepted mDLI because of MRD+. One Ph+ ALL patient had BM-MRD value of BCR-ABL(P190) 4.2%, FCM 0.05%, chimerism of BM 0.72%, chimerism of BM 1 month ago 0.00% and increasing recipient chimerism. However, the chimerism value was lower than 1.0%. Another M2 patient had BM MRD value of AML1/ETO 26.0%, FCM-, chimerism of BM was 0.90%, chimerism value of BM 1 month ago was 0.46% and increasing recipient chimerism. Another two patients accepted mDLI because of WT1 1.2 and 0.96%, respectively, and no increasing recipient chimerism was observed at the same time. Dynamic monitoring of the level of quantitative chimerism after HSCT was important to determine the intensive intervention that should be performed. In the case of a 3-year-old M5 boy, donor was his father with two mismatched loci, the BM recipient chimerism were 23.3, 26.1 and 28.3% at 1, 2 and 3 months after HSCT, the MRD were negative, the boy accepted second HSCT and died due to infection; the patient did not enroll in this study because of the time point of HSCT. Combining quantitative chimerism and MRD analysis does allow accurate determination of engraftment, and surveillance of post-transplant remission status, providing a rational basis for individual preemptive immunotherapy strategies to prevent recurrence of the underlying disease. An important risk of DLI is GVHD. However, no significant differences in patients who received IL-2 or DLI (P = 0.692) in the incidence of 4grade 2 acute GVHD was observed. Our previous study suggested that modified DLI has the same antileukemia efficacy as conventional DLI, but less acute GVHD and better survival. These observations may result from the different composition of the infused cells and short-term use of immunosuppressive drugs. 43, 48 Data from a randomized trial are required to confirm our observation. Huang et al. 49 reported that using G-CSF may indirectly decrease T-cell responses through selective increase of plasmacytoid DC and monocytes, and downregulate the costimulatory signal of CD28/B7. 50 Morris et al. 51 confirmed that using G-CSF during blood-cell mobilization augments the natural killer/T-cell-dependent CD8+ cytotoxicity, purportedly separating GVHD and GVL.
In conclusion, our study clearly demonstrates that quantitative serial analysis of hematopoietic chimerism is a powerful tool for predicting relapse in AL patients after allo-HSCT. The preemptive modified DLI on the basis of increasing quantitative chimerism seems to be a rational and effective treatment option for AL patients. Combining quantitative chimerism and MRD analysis does allow accurate determination of engraftment, and surveillance of posttransplant remission status, providing a rational basis for individual pre-emptive immunotherapy strategies to prevent recurrence of the underlying disease. However, further studies (for example, the use of specific T-cell subsets or gene-modified effector cells) [52] [53] [54] [55] [56] [57] are needed to improve the adjuvant immunotherapy for the prevention of relapse.
